Business Wire

Semperis Enhances the Industry’s Most Comprehensive Active Directory Protection Platform with Continuous Security Validation

4.5.2021 16:00:00 EEST | Business Wire | Press release

Share

Semperis, the pioneer of identity-driven cyber resilience for enterprises, today announced the general availability of Directory Services Protector (DSP) v3.5, which includes DSP Intelligence, a new module that provides automated security assessments of Microsoft Active Directory (AD). DSP Intelligence proactively uncovers dangerous vulnerabilities that arise from external threat actors, systemic weaknesses in default identity and access settings, and even internal configuration drift that leads to security regression.

The company also announced enhancements to Active Directory Forest Recovery (ADFR), the only disaster recovery product for AD purpose-built to combat cyberattacks. New ADFR capabilities include unique backup set encryption keys, advanced forensics search, and extended support for SAML and MFA authentication.

The continuous security assessment capabilities now available in DSP Intelligence address the skyrocketing proliferation of cyberattacks—including the infamous SolarWinds supply-chain attack and the Hafnium attack on Microsoft Exchange—that target identity systems, especially AD. As the gatekeeper to critical applications and data in 90% of organizations worldwide, AD is a common access vector for attackers and extremely complex to secure given its constant flux, sheer number of settings, and the increasingly sophisticated threat landscape. Findings from companies using Semperis’ free Purple Knight security assessment tool revealed that even large organizations with significant investments in security resources are failing to close critical gaps in AD, scoring an average of 61%, with Kerberos authentication being the top risk area.

“Active Directory is a critical piece of most enterprises’ IT infrastructure but is notoriously difficult to keep secure,” said Darren Mar-Elia, Vice President of Products at Semperis. “Not only are its settings complex, but both AD itself and attack paths are constantly evolving. Organizations must be able to ensure their directory services are secure on a continual basis—not just at a point in time—while actively testing against the latest indicators for new attacks and threats. DSP Intelligence is designed to provide a larger range of security indicators and advance pre-attack tests to harden AD against new adversary TTPs and spot your weaknesses before attackers do. The threat hunting capabilities have also proven to be extremely helpful for organizations in post-breach scenarios to understand how attackers broke in and how to close backdoors for good.”

A growing number of breaches involve the exploitation of suboptimal AD configurations to allow attackers to gain a foothold within target networks, access sensitive resources, and deploy malware. To get ahead of attackers, DSP Intelligence continuously queries an organization’s AD environment and performs a comprehensive set of tests against the most common and effective attack vectors that correlate to known security frameworks such as the MITRE ATT&CK.

With the addition of DSP Intelligence, Semperis further establishes DSP as the industry’s most comprehensive AD threat detection and response platform. Semperis also updated the complementary modules, DSP Essential and DSP Advanced, which address foundational directory security and operational use cases:

  • DSP Essential– AD change tracking and rollback
  • DSP Advanced– Autonomous threat protection and response
  • DSP Intelligence – Security validation and breach prevention

To see DSP Intelligence in action, watch the five-minute video overview: https://pages.semperis.com/dsp-intelligence-video-intro/

For more information about DSP and ADFR, visit the product pages below:

About Semperis

For security teams charged with defending hybrid and multi-cloud environments, Semperis ensures integrity and availability of critical enterprise directory services at every step in the cyber kill chain and cuts recovery time by 90%. Purpose-built for securing Active Directory, Semperis’ patented technology protects over 40 million identities from cyberattacks, data breaches, and operational errors. The world’s leading organizations trust Semperis to spot directory vulnerabilities, intercept cyberattacks in progress, and quickly recover from ransomware and other data integrity emergencies. Semperis is headquartered in New Jersey and operates internationally, with its research and development team distributed between San Francisco and Tel Aviv.

Semperis hosts the award-winning Hybrid Identity Protection conference (www.hipconf.com). The company has received the highest level of industry accolades and was recently ranked the fourth fastest-growing company in the tri-state area and 35th overall in Deloitte’s 2020 Technology Fast 500™. Semperis is accredited by Microsoft and recognized by Gartner.

Twitter https://twitter.com/SemperisTech
LinkedIn https://www.linkedin.com/company/semperis
Facebook https://www.facebook.com/SemperisTech
YouTube https://www.youtube.com/channel/UCycrWXhxOTaUQ0sidlyN9SA

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact
Jessica MacGregor
fama PR for Semperis
Semperis@famapr.com
617-986-5024

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 17:50:00 EEST | Press release

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from the two-year estimate, suggesting durable clinical benefit in this population. Responses and long-term survival were observed in both platinum-sensitive and platinum-resistant or refractory disease. At the last follow-up, 25% of patients who received at least one dose of treatment (11 of 44) were alive

emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 18:12:00 EEST | Press release

emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and the right capabilities in the right seats. Sacha brings financial lead

Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 16:00:00 EEST | Press release

Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led global partner and channel operations before becoming President of the company’s Enterprise Service Manageme

EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 16:00:00 EEST | Press release

European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea

ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 15:00:00 EEST | Press release

ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The study demonstrated that a single intranasal dose of BPZE1 induced nasal mucosal immune responses against all Bordetella pertussis antigens tested and was well tolerated, both when administered alone and when co-administered with a tetanus-diphtheria-acellular pertussis (Tdap) booster vaccine. The multi-center Phase 2b trial enrolled 366 participants across 16 sites in the United Kingdom, Australia, and Costa Rica and included participants

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye